{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:25:53Z","timestamp":1772166353276,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Chinese Academy of Medical Sciences Cancer Hospital - Shenzhen Hospital Cooperation Fund","award":["No. CFA202202018"],"award-info":[{"award-number":["No. CFA202202018"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"DOI":"10.1186\/s13048-025-01786-0","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T10:39:34Z","timestamp":1758883174000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PARPis after PARPis in patients with recurrent epithelial ovarian cancer: a single institutional experience"],"prefix":"10.1186","volume":"18","author":[{"given":"Hua","family":"Yuan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tonghui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongwen","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"1786_CR1","first-page":"7","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"1786_CR2","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"1786_CR3","doi-asserted-by":"crossref","unstructured":"Han B, Zheng R, Zeng H, Wang S, Sun K, Chen R, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024;4:47\u201353.","DOI":"10.1016\/j.jncc.2024.01.006"},{"key":"1786_CR4","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","unstructured":"Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609\u201315.","journal-title":"Nature"},{"key":"1786_CR5","volume":"2","author":"A Tattersall","year":"2022","unstructured":"Tattersall A, Ryan N, Wiggans AJ, Rogozi\u0144ska E, Morrison J. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. Cochrane Database Syst Rev. 2022;2:CD007929.","journal-title":"Cochrane Database Syst Rev"},{"key":"1786_CR6","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2019","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381:2391\u2013402.","journal-title":"N Engl J Med"},{"key":"1786_CR7","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard I, Pautier P, Pignata S, P\u00e9rol D, Gonz\u00e1lez-Mart\u00edn A, Berger R, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381:2416\u201328.","journal-title":"N Engl J Med"},{"key":"1786_CR8","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","volume":"381","author":"RL Coleman","year":"2019","unstructured":"Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, et al. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N Engl J Med. 2019;381:2403\u201315.","journal-title":"N Engl J Med"},{"key":"1786_CR9","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1200\/JCO.18.02238","volume":"37","author":"JM Del Campo","year":"2019","unstructured":"Del Campo JM, Matulonis UA, Malander S, Provencher D, Mahner S, Follana P, et al. Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16\/NOVA trial. J Clin Oncol. 2019;37:2968\u201373.","journal-title":"J Clin Oncol"},{"key":"1786_CR10","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/S1470-2045(19)30029-4","volume":"20","author":"KN Moore","year":"2019","unstructured":"Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, et al. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019;20:636\u201348.","journal-title":"Lancet Oncol"},{"key":"1786_CR11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","volume":"18","author":"EM Swisher","year":"2017","unstructured":"Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017;18:75\u201387.","journal-title":"Lancet Oncol"},{"key":"1786_CR12","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","volume":"390","author":"RL Coleman","year":"2017","unstructured":"Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:1949\u201361.","journal-title":"Lancet"},{"key":"1786_CR13","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore K, Colombo N, Scambia G, Kim B-G, Oaknin A, Friedlander M, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379:2495\u2013505.","journal-title":"N Engl J Med"},{"key":"1786_CR14","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","volume":"18","author":"E Pujade-Lauraine","year":"2017","unstructured":"Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1274\u201384.","journal-title":"Lancet Oncol"},{"key":"1786_CR15","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1200\/JCO.19.02745","volume":"38","author":"RT Penson","year":"2020","unstructured":"Penson RT, Valencia RV, Cibula D, Colombo N, Leath CA, Bidzi\u0144ski M, et al. Olaparib versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer and a germline BRCA1\/2 mutation (SOLO3): a randomized phase III trial. J Clin Oncol. 2020;38:1164\u201374.","journal-title":"J Clin Oncol"},{"key":"1786_CR16","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41571-021-00532-x","volume":"18","author":"MP Dias","year":"2021","unstructured":"Dias MP, Moser SC, Ganesan S, Jonkers J. Understanding and overcoming resistance to PARP inhibitors in cancer therapy. Nat Rev Clin Oncol. 2021;18:773\u201391.","journal-title":"Nat Rev Clin Oncol"},{"key":"1786_CR17","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13048-024-01400-9","volume":"17","author":"H Yuan","year":"2024","unstructured":"Yuan H, Li N, Wu L, Yao H. Subsequent management and outcomes after first-line PARP inhibitors progression in ovarian cancer patients. J Ovarian Res. 2024;17:70.","journal-title":"J Ovarian Res"},{"key":"1786_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2022.100939","volume":"40","author":"M Moubarak","year":"2022","unstructured":"Moubarak M, Harter P, Ataseven B, Traut A, Welz J, Baert T, et al. Re-treatment with PARPi in patients with recurrent epithelial ovarian cancer: a single institutional experience. Gynecol Oncol Rep. 2022;40:100939.","journal-title":"Gynecol Oncol Rep"},{"key":"1786_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2021.100699","volume":"35","author":"KG Essel","year":"2021","unstructured":"Essel KG, Behbakht K, Lai T, Hand L, Evans E, Dvorak J, et al. PARpi after PARpi in epithelial ovarian cancer. Gynecol Oncol Rep. 2021;35:100699.","journal-title":"Gynecol Oncol Rep"},{"key":"1786_CR20","doi-asserted-by":"crossref","unstructured":"Pujade-Lauraine E, Selle F, Scambia G, Asselain B, Marm\u00e9 F, Lindemann K, et al. Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO\/ENGOT-ov38): a phase IIIb trial.\u00a0Ann Oncol. 2023;34:1152\u201364.","DOI":"10.1016\/j.annonc.2023.09.3110"},{"key":"1786_CR21","doi-asserted-by":"publisher","first-page":"5558","DOI":"10.1200\/JCO.2022.40.16_suppl.5558","volume":"40","author":"F Selle","year":"2022","unstructured":"Selle F, Asselain B, Montestruc F, Bazan F, Pardo B, Salutari V, et al. OReO\/ENGOT Ov-38 trial: impact of maintenance olaparib rechallenge according to ovarian cancer patient prognosis\u2014an exploratory joint analysis of the BRCA and non-BRCA cohorts. JCO. 2022;40:5558\u20135558.","journal-title":"JCO"},{"key":"1786_CR22","doi-asserted-by":"crossref","unstructured":"Jou J, Kurzrock R, Zajchowski D, Eskander R. PARpi post PARpi: clarity from the clearity real world experience. Gynecol Oncol. 2022;166:S97.","DOI":"10.1016\/S0090-8258(22)01391-9"},{"key":"1786_CR23","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.3802\/jgo.2024.35.e51","volume":"35","author":"H Yuan","year":"2024","unstructured":"Yuan H, Xiu L, Li N, Li Y, Wu L, Yao H. PARPis response and outcome of ovarian cancer patients with BRCA1\/2 germline mutation and a history of breast cancer. J Gynecol Oncol. 2024;35:e51.","journal-title":"J Gynecol Oncol"},{"key":"1786_CR24","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1200\/CCI.20.00125","volume":"5","author":"B Walker","year":"2021","unstructured":"Walker B, Boyd M, Aguilar K, Davies K, Espirito J, Frytak J, et al. Comparisons of real-world time-to-event end points in oncology research. JCO Clin Cancer Inform. 2021;5:45\u20136.","journal-title":"JCO Clin Cancer Inform"},{"key":"1786_CR25","doi-asserted-by":"publisher","first-page":"S1308","DOI":"10.1016\/j.annonc.2021.08.2110","volume":"32","author":"E Pujade-Lauraine","year":"2021","unstructured":"Pujade-Lauraine E. Maintenance olaparib rechallenge in patients (pts) with ovarian carcinoma (OC) previously treated with a PARP inhibitor (PARPi): Phase IIIb OReO\/ENGOT Ov-38 trial. Ann Oncol. 2021;32:S1308-1309.","journal-title":"Ann Oncol"},{"key":"1786_CR26","doi-asserted-by":"crossref","unstructured":"Jou J, Kurzrock R, Zajchowski D, Eskander R. PARPi post PARPi: Clarity from the Clearity real world experience.\u00a0Gynecol Oncol. 2022;166:S97.","DOI":"10.1016\/S0090-8258(22)01391-9"},{"key":"1786_CR27","doi-asserted-by":"publisher","first-page":"4206","DOI":"10.1158\/1078-0432.CCR-19-4121","volume":"26","author":"S Lheureux","year":"2020","unstructured":"Lheureux S, Oaknin A, Garg S, Bruce JP, Madariaga A, Dhani NC, et al. Evolve: a multicenter open-label single-arm clinical and translational phase II trial of cediranib plus olaparib for ovarian cancer after PARP inhibition progression. Clin Cancer Res. 2020;26:4206\u201315.","journal-title":"Clin Cancer Res"},{"key":"1786_CR28","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/S0090-8258(21)00656-9","volume":"162","author":"R Kristeleit","year":"2021","unstructured":"Kristeleit R, Lisyanskaya A, Fedenko A, Dvorkin M, de Melo AC, Shparyk Y, et al. Rucaparib versus chemotherapy in patients with advanced, relapsed ovarian cancer and a deleterious BRCA mutation: efficacy and safety from ARIEL4, a randomized phase III study. Gynecol Oncol. 2021;162:S3-4.","journal-title":"Gynecol Oncol"},{"key":"1786_CR29","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1136\/ijgc-2020-001694","volume":"30","author":"M McMullen","year":"2020","unstructured":"McMullen M, Karakasis K, Loembe B, Dean E, Parr G, Oza AM. Duette: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment. Int J Gynecol Cancer. 2020;30:1824\u20138.","journal-title":"Int J Gynecol Cancer"},{"key":"1786_CR30","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.3802\/jgo.2022.33.e12","volume":"33","author":"J Park","year":"2022","unstructured":"Park J, Lim MC, Lee J-K, Jeong DH, Kim SI, Choi MC, et al. A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)\/nirvana-r trial. J Gynecol Oncol. 2022;33:e12.","journal-title":"J Gynecol Oncol"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-025-01786-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-025-01786-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-025-01786-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T10:39:38Z","timestamp":1758883178000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-025-01786-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1786"],"URL":"https:\/\/doi.org\/10.1186\/s13048-025-01786-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4905090\/v1","asserted-by":"object"}]},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"13 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Research and Ethics Committee of Cancer Hospital, Chinese Academy of Medical Sciences, National Cancer Center. Investigation was conducted in accordance with ethical standards, the Declaration of Helsinki and Chinese and international guidelines.Informed consent was diligently obtained from all enrolled patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"206"}}